PJ2 Share Price Performance
€0
0.00 (0.00%)
Price €0
Share Pricen/a
Liminal BioSciences Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
PJ2 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Liminal BioSciences Inc. Key Details
Last Reported Earnings
Dec 31, 2022
Next Reporting Earnings
n/a
- -9.35
- -3,714.96%
- -7,241.40%
- 0%
About PJ2
- Founded
- 1994
- Employees
- n/a
- CEO
- WebsiteView website
Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
